Free Trial
→ Read this or regret it forever (From Porter & Company) (Ad)tc pixel Free RARE Stock Alerts

Ultragenyx Pharmaceutical (RARE) Financials

Ultragenyx Pharmaceutical logo
$25.80 -0.66 (-2.49%)
Closing price 04:00 PM Eastern
Extended Trading
$25.73 -0.07 (-0.27%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Ultragenyx Pharmaceutical

Annual Income Statements for Ultragenyx Pharmaceutical

This table shows Ultragenyx Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
Consolidated Net Income / (Loss)		 -146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
Net Income / (Loss) Continuing Operations		 -146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
Total Pre-Tax Income 		-146 -246 -318 -197 -399 -185 -453 -702 -609 -567 -571
Total Operating Income		 -148 -248 -329 -371 -424 -330 -382 -649 -569 -536 -535
Total Gross Profit		 0.00 0.13 2.61 50 95 265 335 335 389 483 564
Total Revenue		 0.00 0.13 2.61 51 104 271 351 363 434 560 673
Operating Revenue		 0.00 0.13 2.61 51 104 271 351 363 434 560 673
Total Cost of Revenue		 0.00 0.00 0.00 1.15 9.01 6.13 16 28 45 77 109
Operating Cost of Revenue		 0.00 0.00 0.00 1.15 9.01 6.13 16 28 45 77 109
Total Operating Expenses		 148 248 332 422 519 595 717 984 958 1,019 1,099
Selling, General & Admin Expense		 33 65 100 128 162 183 220 278 310 321 349
Research & Development Expense		 115 183 232 294 357 412 497 706 648 698 750
Total Other Income / (Expense), net		 2.12 2.17 11 174 25 145 -71 -53 -40 -31 -36
Interest Expense		 - - 0.00 0.00 1.14 33 29 43 66 63 62
Interest & Investment Income		 2.32 3.79 4.07 9.54 27 177 -40 -8.23 27 37 25
Other Income / (Expense), net		 -0.20 -1.62 6.53 165 -0.79 0.61 -1.69 -1.57 -1.00 -5.00 1.00
Income Tax Expense		 0.00 0.04 -16 0.51 3.28 1.21 1.04 5.70 -2.00 2.00 4.00
Basic Earnings per Share		 ($3.96) ($6.21) ($7.12) ($3.97) ($7.12) ($3.07) ($6.70) ($10.12) ($8.25) ($6.29) ($5.83)
Weighted Average Basic Shares Outstanding		 36.78M 39.59M 42.45M 49.78M 56.58M 60.85M 67.80M 69.91M 73.50M 90.50M 98.60M
Diluted Earnings per Share		 ($3.96) ($6.21) ($7.12) ($3.97) ($7.12) ($3.07) ($6.70) ($10.12) ($8.25) ($6.29) ($5.83)
Weighted Average Diluted Shares Outstanding		 36.78M 39.59M 42.45M 49.78M 56.58M 60.85M 67.80M 69.91M 73.50M 90.50M 98.60M
Weighted Average Basic & Diluted Shares Outstanding		 36.78M 39.59M 42.45M 49.78M 56.58M 60.85M 67.80M 70.22M 82.34M 92.50M 96.63M

Quarterly Income Statements for Ultragenyx Pharmaceutical

This table shows Ultragenyx Pharmaceutical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -160 -123 -171 -132 -134 -133 -151 -115 -180 -129 -185
Consolidated Net Income / (Loss)		 -160 -123 -171 -132 -134 -133 -151 -115 -180 -129 -185
Net Income / (Loss) Continuing Operations		 -160 -123 -171 -132 -134 -133 -151 -115 -180 -129 -185
Total Pre-Tax Income 		-159 -127 -170 -131 -133 -133 -150 -114 -180 -128 -184
Total Operating Income		 -145 -122 -165 -116 -132 -122 -143 -108 -171 -113 -169
Total Gross Profit		 87 115 91 126 118 148 110 143 132 178 106
Total Revenue		 98 127 109 147 139 165 139 166 160 207 136
Operating Revenue		 98 127 109 147 139 165 139 166 160 207 136
Total Cost of Revenue		 11 12 18 21 21 17 29 23 28 29 30
Operating Cost of Revenue		 11 12 18 21 21 17 29 23 28 29 30
Total Operating Expenses		 232 237 257 242 250 270 253 251 303 291 275
Selling, General & Admin Expense		 75 77 78 81 80 82 87 87 87 88 88
Research & Development Expense		 157 161 178 162 170 188 166 165 216 203 187
Total Other Income / (Expense), net		 -14 -4.84 -4.88 -14 -1.23 -11 -7.00 -6.12 -8.65 -14 -15
Interest Expense		 18 17 16 16 16 16 14 14 14 19 21
Interest & Investment Income		 4.46 10 13 3.41 11 8.00 7.00 5.79 6.54 6.00 6.00
Income Tax Expense		 0.65 -3.70 0.46 0.86 0.30 -0.02 1.00 0.95 0.87 0.87 1.00
Basic Earnings per Share		 ($2.23) ($1.44) ($2.03) ($1.52) ($1.40) ($1.34) ($1.57) ($1.17) ($1.81) ($1.28) ($1.84)
Weighted Average Basic Shares Outstanding		 71.66M 73.54M 84.29M 86.58M 95.49M 90.54M 96.30M 98.46M 99.77M 98.60M 100.60M
Diluted Earnings per Share		 ($2.23) ($1.44) ($2.03) ($1.52) ($1.40) ($1.34) ($1.57) ($1.17) ($1.81) ($1.28) ($1.84)
Weighted Average Diluted Shares Outstanding		 71.66M 73.54M 84.29M 86.58M 95.49M 90.54M 96.30M 98.46M 99.77M 98.60M 100.60M
Weighted Average Basic & Diluted Shares Outstanding		 82.11M 82.34M 83.13M 92.17M 92.34M 92.50M 94.54M 96.37M 96.48M 96.63M 98.49M

Annual Cash Flow Statements for Ultragenyx Pharmaceutical

This table details how cash moves in and out of Ultragenyx Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 69 69 -62 13 321 290 -417 -172 81 -35 252
Net Cash From Operating Activities		 -106 -161 -254 -291 -345 -132 -339 -380 -475 -414 -466
Net Cash From Continuing Operating Activities		 -106 -161 -254 -291 -345 -132 -339 -384 -475 -414 -466
Net Income / (Loss) Continuing Operations		 -146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
Consolidated Net Income / (Loss)		 -146 -246 -302 -198 -403 -187 -454 -707 -607 -569 -575
Depreciation Expense		 1.38 3.42 5.83 20 8.54 12 13 18 26 36 35
Amortization Expense		 5.64 4.84 1.71 -2.64 -6.21 0.85 6.61 2.70 -13 -13 -4.00
Non-Cash Adjustments To Reconcile Net Income		 25 50 61 -85 72 3.14 101 246 135 118 101
Changes in Operating Assets and Liabilities, net		 7.74 26 -20 -25 -17 38 -5.74 56 -16 14 -23
Net Cash From Investing Activities		 -292 91 55 -33 -13 -179 -195 -292 168 -18 236
Net Cash From Continuing Investing Activities		 -292 91 55 -33 -13 -179 -195 -292 168 -18 236
Purchase of Property, Plant & Equipment		 -4.96 -10 -2.79 -4.08 -25 -44 -73 -116 -44 -7.00 -6.00
Acquisitions		 0.00 0.00 -143 0.00 -14 -37 0.00 -105 -3.00 -13 -15
Purchase of Investments		 -624 -442 -230 -510 -693 -813 -1,012 -615 -526 -409 -186
Sale and/or Maturity of Investments		 338 544 432 310 719 721 891 545 747 413 444
Other Investing Activities, net		 -1.54 - - 0.00 0.00 -5.56 -0.94 -0.84 -6.00 -2.00 -1.00
Net Cash From Financing Activities		 468 139 136 337 679 600 119 501 388 399 478
Net Cash From Continuing Financing Activities		 468 139 136 337 679 600 119 501 388 399 478
Repayment of Debt		 0.00 0.00 -4.94 0.00 0.00 -0.24 -0.49 -0.56 1.00 0.00 0.00
Issuance of Common Equity		 468 139 141 337 365 601 119 11 387 399 86
Other Financing Activities, net		 - - 0.00 0.00 314 0.00 0.00 491 0.00 0.00 392
Effect of Exchange Rate Changes		 0.00 -0.07 0.53 - -0.17 1.12 -1.19 -1.08 0.00 -2.00 4.00

Quarterly Cash Flow Statements for Ultragenyx Pharmaceutical

This table details how cash moves in and out of Ultragenyx Pharmaceutical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -29 141 -97 368 -330 24 -45 49 26 221 -247
Net Cash From Operating Activities		 -118 -84 -191 -77 -67 -80 -166 -108 -91 -100 -197
Net Cash From Continuing Operating Activities		 -118 -84 -191 -77 -67 -80 -166 -108 -91 -100 -197
Net Income / (Loss) Continuing Operations		 -160 -123 -171 -132 -134 -133 -151 -115 -180 -129 -185
Consolidated Net Income / (Loss)		 -160 -123 -171 -132 -134 -133 -151 -115 -180 -129 -185
Depreciation Expense		 7.19 8.22 8.85 8.86 8.76 9.08 9.00 8.62 8.61 8.79 8.00
Amortization Expense		 -2.68 -3.95 -3.76 -2.95 -3.12 -2.81 -2.00 -1.05 -0.70 -0.52 -1.00
Non-Cash Adjustments To Reconcile Net Income		 34 22 31 32 30 25 34 21 26 20 32
Changes in Operating Assets and Liabilities, net		 2.80 13 -56 16 31 23 -56 -22 55 0.59 -51
Net Cash From Investing Activities		 64 -107 94 61 -276 103 120 71 117 -72 -49
Net Cash From Continuing Investing Activities		 64 -107 94 61 -276 103 120 71 117 -72 -49
Purchase of Property, Plant & Equipment		 -3.70 -1.60 -3.21 -2.01 -1.62 -0.65 -1.00 -2.46 -1.28 -0.94 -1.00
Acquisitions		 - - -10 -2.50 - - -15 - - - -5.00
Purchase of Investments		 -139 -222 -22 -3.37 -367 -16 0.00 -16 -17 -154 -131
Sale and/or Maturity of Investments		 208 116 132 68 94 119 137 89 136 82 88
Other Investing Activities, net		 -0.43 -0.27 -2.07 -0.04 -0.20 -0.13 -1.00 -0.31 -0.19 0.27 0.00
Net Cash From Financing Activities		 25 331 -0.06 385 11 3.19 0.00 84 0.00 394 0.00
Net Cash From Continuing Financing Activities		 25 331 -0.06 385 11 3.19 0.00 84 0.00 394 0.00
Effect of Exchange Rate Changes		 -0.72 1.10 -0.68 -0.65 1.28 -2.47 1.00 2.91 0.29 -0.66 -1.00

Annual Balance Sheets for Ultragenyx Pharmaceutical

This table presents Ultragenyx Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 560 541 491 720 1,135 1,760 1,522 1,545 1,491 1,503 1,532
Total Current Assets		 450 402 270 522 851 1,295 857 884 732 817 951
Cash & Equivalents		 94 161 100 113 434 714 308 133 214 174 421
Short-Term Investments		 343 219 134 346 322 488 433 615 364 436 259
Accounts Receivable		 - 0.00 5.17 13 33 23 28 40 73 122 158
Inventories, net		 - 0.00 0.76 7.07 12 13 16 27 34 45 52
Prepaid Expenses		 13 20 29 43 51 58 72 - 48 40 61
Plant, Property, & Equipment, net		 7.37 17 22 20 44 74 141 260 291 266 244
Total Noncurrent Assets		 102 122 199 177 240 391 525 402 468 420 337
Long-Term Investments		 99 118 9.98 0.00 5.17 11 294 149 200 135 57
Goodwill		 - 0.00 44 44 44 44 44 44 44 44 44
Intangible Assets		 - 0.00 142 129 129 131 131 160 166 178 176
Other Noncurrent Operating Assets		 0.60 1.84 3.41 3.51 62 205 55 48 58 63 60
Total Liabilities & Shareholders' Equity		 560 541 491 720 1,135 1,760 1,522 1,545 1,491 1,503 1,532
Total Liabilities		 28 67 107 111 482 605 600 1,193 1,216 1,241 1,605
Total Current Liabilities		 28 60 71 75 103 190 181 261 280 344 384
Accounts Payable		 2.94 5.36 8.89 12 13 13 17 43 42 39 31
Accrued Expenses		 25 55 62 62 83 108 146 205 196 241 265
Other Current Liabilities		 - - - 0.00 7.24 68 19 13 42 64 88
Total Noncurrent Liabilities		 0.56 6.39 36 36 378 416 418 932 935 897 1,221
Noncurrent Deferred & Payable Income Tax Liabilities		 - 0.00 31 31 33 33 33 32 30 30 30
Other Noncurrent Operating Liabilities		 0.56 6.39 5.12 4.76 345 382 385 900 905 867 1,191
Redeemable Noncontrolling Interest		 - - - - - - - - 0.00 7.00 7.00
Total Equity & Noncontrolling Interests		 531 474 383 609 654 1,154 923 352 275 255 -80
Total Preferred & Common Equity		 531 474 383 609 654 1,154 923 352 275 255 -80
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 531 474 383 609 654 1,154 923 352 275 255 -80
Common Stock		 817 1,004 1,222 1,640 2,087 2,773 2,998 3,140 3,662 4,213 4,451
Retained Earnings		 -285 -531 -833 -1,030 -1,433 -1,620 -2,074 -2,781 -3,388 -3,957 -4,532
Treasury Stock		 - - - - - - - 0.00 -0.43 -4.00 -8.00
Accumulated Other Comprehensive Income / (Loss)		 -0.87 0.91 -5.68 -0.63 -0.15 0.69 -1.40 -6.57 0.65 -1.00 1.00
Other Equity Adjustments		 - - - - - - - 0.00 0.43 4.00 8.00

Quarterly Balance Sheets for Ultragenyx Pharmaceutical

This table presents Ultragenyx Pharmaceutical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1,618 1,383 1,311 1,238 1,307 1,618 1,538 1,312 1,306 1,190 1,296
Total Current Assets		 1,013 766 702 599 596 965 800 699 720 643 657
Cash & Equivalents		 392 86 102 73 112 481 151 127 176 203 175
Short-Term Investments		 497 544 450 370 300 283 471 367 311 223 238
Accounts Receivable		 31 43 71 79 100 106 93 99 124 113 121
Inventories, net		 22 27 28 32 36 40 43 46 46 52 55
Prepaid Expenses		 71 67 51 46 0.00 - - 60 61 53 68
Plant, Property, & Equipment, net		 235 278 289 297 285 279 272 261 256 250 239
Total Noncurrent Assets		 371 339 320 342 426 375 466 352 331 297 400
Long-Term Investments		 121 90 72 86 157 111 203 69 51 22 121
Goodwill		 44 44 44 44 44 44 44 44 44 44 44
Intangible Assets		 158 159 158 157 165 166 165 177 175 173 174
Other Noncurrent Operating Assets		 47 45 46 54 60 54 54 62 60 58 61
Total Liabilities & Shareholders' Equity		 1,618 1,383 1,311 1,238 1,307 1,618 1,538 1,312 1,306 1,190 1,296
Total Liabilities		 1,150 1,163 1,182 1,206 1,167 1,186 1,185 1,161 1,148 1,174 1,525
Total Current Liabilities		 227 218 244 254 246 273 285 292 293 340 325
Accounts Payable		 24 59 42 33 41 60 36 47 34 41 42
Accrued Expenses		 189 144 168 179 149 154 185 173 181 221 194
Other Current Liabilities		 15 15 35 42 55 59 64 71 78 79 89
Total Noncurrent Liabilities		 922 945 938 952 921 913 900 869 855 834 1,200
Noncurrent Deferred & Payable Income Tax Liabilities		 33 32 32 32 30 30 30 30 30 30 30
Other Noncurrent Operating Liabilities		 889 913 906 921 891 883 869 839 825 804 1,170
Redeemable Noncontrolling Interest		 - - - - - - 7.00 7.00 7.00 7.00 7.00
Total Equity & Noncontrolling Interests		 469 220 129 32 140 432 347 144 151 9.16 -236
Total Preferred & Common Equity		 469 220 129 32 140 432 347 144 151 9.16 -236
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 469 220 129 32 140 432 347 144 151 9.16 -236
Common Stock		 3,108 3,169 3,237 3,298 3,699 4,123 4,169 4,253 4,374 4,412 4,481
Retained Earnings		 -2,629 -2,945 -3,105 -3,264 -3,558 -3,690 -3,823 -4,108 -4,223 -4,403 -4,717
Treasury Stock		 - -0.36 -0.38 -0.38 -3.33 -3.40 -3.56 -7.57 -7.99 -7.99 -10
Accumulated Other Comprehensive Income / (Loss)		 -10 -3.97 -3.10 -2.24 -0.43 -1.10 0.90 -0.34 -0.27 0.82 0.00
Other Equity Adjustments		 - 0.36 0.38 0.38 3.33 3.40 3.56 7.57 7.99 7.99 10

Annual Metrics And Ratios for Ultragenyx Pharmaceutical

This table displays calculated financial ratios and metrics derived from Ultragenyx Pharmaceutical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 1,863.91% 1,871.48% 101.41% 161.32% 29.66% 3.39% 19.52% 29.01% 20.18%
EBITDA Growth		 -151.07% -71.28% -30.46% 39.74% -122.74% 25.14% -14.91% -73.16% 11.62% 7.08% 2.90%
EBIT Growth		 -144.89% -68.74% -29.16% 35.91% -105.65% 22.46% -16.36% -69.65% 12.44% 5.20% 1.29%
NOPAT Growth		 -160.20% -67.87% -32.63% -12.90% -14.22% 22.17% -15.64% -69.99% 12.28% 5.84% 0.19%
Net Income Growth		 -143.50% -68.85% -22.88% 34.60% -103.80% 53.67% -143.36% -55.81% 14.25% 6.17% -1.05%
EPS Growth		 -76.00% -56.82% -14.65% 44.24% -79.35% 56.88% -118.24% -51.04% 18.48% 23.76% 7.31%
Operating Cash Flow Growth		 -137.44% -51.90% -57.69% -14.47% -18.87% 61.72% -156.16% -12.33% -24.80% 12.77% -12.56%
Free Cash Flow Firm Growth		 -170.01% -54.59% -158.66% 31.92% 84.80% -581.75% 23.81% 89.93% -1,951.27% 10.62% 87.94%
Invested Capital Growth		 -126.75% -270.74% 603.14% 7.35% -171.47% 45.93% -93.35% -388.14% 7.82% 3.78% -67.70%
Revenue Q/Q Growth		 0.00% 3.91% 1,186.70% 36.78% 22.91% 26.01% -2.27% 5.81% 5.86% 7.17% 6.72%
EBITDA Q/Q Growth		 -37.13% -7.42% -8.81% 3.92% -1.26% 0.44% -1.48% -7.66% 4.53% -0.76% 2.64%
EBIT Q/Q Growth		 -36.06% -6.86% -8.96% 3.89% -0.95% -0.45% -1.91% -6.99% 4.28% -1.10% 2.14%
NOPAT Q/Q Growth		 -36.14% -6.16% -8.68% 1.72% -0.98% -0.50% -1.73% -7.11% 3.98% -0.04% 1.65%
Net Income Q/Q Growth		 -35.92% -6.99% -3.58% -3.18% -1.51% 27.23% -27.69% -4.33% 4.51% -1.82% 0.83%
EPS Q/Q Growth		 -34.69% -4.90% -2.01% 2.70% 2.33% 30.07% -28.35% -4.01% 8.13% 1.56% 1.02%
Operating Cash Flow Q/Q Growth		 -35.89% -4.71% -15.54% 8.20% -4.92% 6.76% 2.34% -10.45% 1.34% 1.05% -4.56%
Free Cash Flow Firm Q/Q Growth		 -36.80% -2.76% -99.07% 40.85% 87.90% -237.43% 46.31% -192.68% 4.06% 1.62% 88.70%
Invested Capital Q/Q Growth		 -23.69% -36.50% 524.54% -6.46% -152.00% 74.78% -18.73% -0.56% -1.05% -2.52% -87.87%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 99.96% 97.77% 91.31% 97.74% 95.44% 92.21% 89.59% 86.30% 83.80%
EBITDA Margin		 0.00% -181,475.19% -12,055.17% -368.47% -407.50% -116.74% -103.46% -173.28% -128.12% -92.29% -74.74%
Operating Margin		 0.00% -186,471.43% -12,593.49% -721.18% -408.98% -121.80% -108.63% -178.60% -131.08% -95.67% -79.49%
EBIT Margin		 0.00% -187,690.23% -12,343.49% -401.28% -409.74% -121.58% -109.11% -179.03% -131.16% -96.38% -79.35%
Profit (Net Income) Margin		 0.00% -184,867.67% -11,567.34% -383.75% -388.31% -68.84% -129.20% -194.71% -139.70% -101.60% -85.44%
Tax Burden Percent		 100.00% 100.01% 94.91% 100.26% 100.82% 100.65% 100.23% 100.81% 99.70% 100.28% 100.70%
Interest Burden Percent		 98.43% 98.48% 98.74% 95.38% 94.00% 56.25% 118.14% 107.88% 106.83% 105.12% 106.93%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -413.53% -180.41% -1,395.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -394.26% -198.12% -1,377.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 343.06% 140.58% 1,331.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -40.67% -48.93% -70.48% -39.83% -63.79% -20.64% -43.72% -110.96% -193.23% -211.71% -608.47%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -285.55% -187.50% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -45.38% -62.52% -34.15% -45.82% -22.76% -23.37% -42.41% -37.51% -36.06% -35.19%
Return on Assets (ROA)		 0.00% -44.70% -58.59% -32.65% -43.42% -12.89% -27.67% -46.12% -39.96% -38.02% -37.89%
Return on Common Equity (ROCE)		 -40.67% -48.93% -70.48% -39.83% -63.79% -20.64% -43.72% -110.96% -193.23% -208.95% -563.39%
Return on Equity Simple (ROE_SIMPLE)		 -27.42% -51.88% -78.79% -32.45% -61.60% -16.16% -49.21% -200.69% -220.26% -222.95% 0.00%
Net Operating Profit after Tax (NOPAT)		 -103 -174 -230 -260 -297 -231 -267 -454 -398 -375 -375
NOPAT Margin		 0.00% -130,530.00% -8,815.44% -504.83% -286.29% -85.26% -76.04% -125.02% -91.76% -66.97% -55.65%
Net Nonoperating Expense Percent (NNEP)		 -11.61% -13.90% -19.27% 17.71% -17.34% 4.51% -16.63% -26.23% -24.88% -25.49% -27.06%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -128.87% -144.67% -146.96% 468.13%
Cost of Revenue to Revenue		 0.00% 0.00% 0.04% 2.23% 8.69% 2.26% 4.56% 7.79% 10.41% 13.70% 16.20%
SG&A Expenses to Revenue		 0.00% 48,824.06% 3,825.00% 248.03% 155.74% 67.50% 62.60% 76.55% 71.34% 57.41% 51.86%
R&D to Revenue		 0.00% 137,747.37% 8,868.45% 570.93% 344.56% 152.04% 141.48% 194.26% 149.33% 124.57% 111.44%
Operating Expenses to Revenue		 0.00% 186,571.43% 12,693.45% 818.96% 500.30% 219.54% 204.08% 270.81% 220.67% 181.97% 163.30%
Earnings before Interest and Taxes (EBIT)		 -148 -250 -322 -207 -425 -330 -383 -650 -570 -540 -534
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -141 -241 -315 -190 -423 -316 -364 -630 -556 -517 -503
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 8.20 6.06 5.15 3.61 3.77 7.32 6.21 9.21 14.26 15.22 0.00
Price to Tangible Book Value (P/TBV)		 8.20 6.06 10.00 5.05 5.14 8.63 7.67 21.95 60.66 119.25 0.00
Price to Revenue (P/Rev)		 0.00 21,600.43 756.23 42.71 23.79 31.18 16.31 8.94 9.04 6.93 3.30
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 12.45 11.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 17,844.62 662.64 33.78 16.46 26.71 13.37 6.47 7.25 5.62 2.21
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -0.87 -0.71 -0.97 -1.09 -1.08 -1.51 -2.67 -2.83 -7.84
Leverage Ratio		 1.06 1.09 1.20 1.22 1.47 1.60 1.58 2.41 4.84 5.57 16.06
Compound Leverage Factor		 1.04 1.08 1.19 1.16 1.38 0.90 1.87 2.60 5.17 5.85 17.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.67% -9.59%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 97.33% 109.59%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 91.10 23.72 6.99 9.79 0.95 7.38 3.76 -1.56 -1.85 -2.24 -3.58
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.30% 7.41%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.13 6.67 3.80 6.99 8.24 6.83 4.72 3.38 2.61 2.37 2.48
Quick Ratio		 15.65 6.31 3.37 6.32 7.63 6.46 4.24 3.02 2.32 2.13 2.18
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -99 -153 -397 -270 -41 -280 -213 -21 -441 -394 -48
Operating Cash Flow to CapEx		 -2,138.79% -1,580.05% -9,088.54% -7,128.70% -1,390.88% -301.15% -463.38% -327.64% -1,072.60% -5,529.14% -7,766.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -36.19 -8.41 -7.25 -0.50 -6.68 -6.25 -0.77
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -304.30 -3.97 -11.51 -8.84 -7.19 -6.57 -7.52
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -326.18 -5.29 -14.00 -11.54 -7.86 -6.69 -7.61
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.09 0.11 0.19 0.21 0.24 0.29 0.37 0.44
Accounts Receivable Turnover		 0.00 0.00 0.00 5.75 4.55 9.69 13.64 10.55 7.63 5.74 4.81
Inventory Turnover		 0.00 0.00 0.00 0.29 0.97 0.50 1.09 1.32 1.49 1.94 2.25
Fixed Asset Turnover		 0.00 0.01 0.13 2.46 3.22 4.60 3.27 1.81 1.58 2.01 2.64
Accounts Payable Turnover		 0.00 0.00 0.00 0.11 0.72 0.48 1.07 0.94 1.06 1.90 3.11
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 63.48 80.21 37.67 26.76 34.60 47.84 63.59 75.93
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 1,245.65 377.05 732.32 333.80 277.08 245.18 187.85 162.41
Days Payable Outstanding (DPO)		 0.00 0.00 2,600,625.00 3,369.88 509.45 768.05 342.71 389.31 344.69 192.35 117.20
Cash Conversion Cycle (CCC)		 0.00 0.00 -2,600,625.00 -2,060.75 -52.19 1.93 17.84 -77.63 -51.68 59.08 121.14
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -7.45 -28 139 149 -107 -58 -111 -544 -502 -483 -810
Invested Capital Turnover		 0.00 -0.01 0.05 0.36 4.87 -3.30 -4.15 -1.11 -0.83 -1.14 -1.04
Increase / (Decrease) in Invested Capital		 -4.17 -20 167 10 -256 49 -54 -433 43 19 -327
Enterprise Value (EV)		 3,820 2,373 1,731 1,739 1,707 7,238 4,698 2,351 3,150 3,147 1,489
Market Capitalization		 4,356 2,873 1,975 2,199 2,467 8,450 5,732 3,248 3,927 3,885 2,219
Book Value per Share		 $13.68 $11.60 $9.00 $12.04 $11.32 $18.91 $13.53 $5.03 $3.35 $2.76 ($0.83)
Tangible Book Value per Share		 $13.68 $11.60 $4.64 $8.61 $8.31 $16.04 $10.96 $2.11 $0.79 $0.35 ($3.11)
Total Capital		 531 474 383 609 654 1,154 923 352 275 262 -73
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -536 -500 -244 -460 -760 -1,212 -1,034 -897 -777 -745 -737
Capital Expenditures (CapEx)		 4.96 10 2.79 4.08 25 44 73 116 44 7.49 6.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -40 -36 -12 -7.51 -96 -65 -125 -125 -137 -113
Debt-free Net Working Capital (DFNWC)		 422 341 199 448 748 1,106 675 623 452 473 567
Net Working Capital (NWC)		 422 341 199 448 748 1,106 675 623 452 473 567
Net Nonoperating Expense (NNE)		 42 72 72 -62 106 -45 187 253 208 194 201
Net Nonoperating Obligations (NNO)		 -539 -502 -244 -460 -760 -1,212 -1,034 -897 -777 -745 -737
Total Depreciation and Amortization (D&A)		 7.02 8.27 7.53 17 2.33 13 20 21 13 23 31
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -30,167.67% -1,375.34% -23.42% -7.24% -35.36% -18.49% -34.42% -28.89% -24.46% -16.79%
Debt-free Net Working Capital to Revenue		 0.00% 256,718.80% 7,602.18% 869.30% 720.94% 407.96% 192.15% 171.38% 104.03% 84.42% 84.25%
Net Working Capital to Revenue		 0.00% 256,718.80% 7,602.18% 869.30% 720.94% 407.96% 192.15% 171.38% 104.03% 84.42% 84.25%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.96) ($6.21) ($7.12) ($3.97) ($7.12) ($3.07) ($6.70) ($10.12) ($8.25) ($6.29) ($5.83)
Adjusted Weighted Average Basic Shares Outstanding		 38.98M 41.73M 49.61M 51.28M 57.89M 66.95M 69.38M 69.91M 73.54M 90.54M 98.60M
Adjusted Diluted Earnings per Share		 ($3.96) ($6.21) ($7.12) ($3.97) ($7.12) ($3.07) ($6.70) ($10.12) ($8.25) ($6.29) ($5.83)
Adjusted Weighted Average Diluted Shares Outstanding		 38.98M 41.73M 49.61M 51.28M 57.89M 66.95M 69.38M 69.91M 73.54M 90.54M 98.60M
Adjusted Basic & Diluted Earnings per Share		 ($3.96) ($6.21) ($7.12) ($3.97) ($7.12) ($3.07) ($6.70) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 36.78M 39.59M 42.45M 49.78M 56.58M 60.85M 67.80M 70.22M 82.34M 92.50M 96.63M
Normalized Net Operating Profit after Tax (NOPAT)		 -103 -174 -230 -260 -297 -231 -267 -454 -398 -375 -375
Normalized NOPAT Margin		 0.00% -130,530.00% -8,815.44% -504.83% -286.29% -85.26% -76.04% -125.02% -91.76% -66.97% -55.65%
Pre Tax Income Margin		 0.00% -184,841.35% -12,187.52% -382.75% -385.14% -68.39% -128.91% -193.14% -140.12% -101.31% -84.84%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -374.41 -9.90 -13.03 -15.12 -8.63 -8.56 -8.61
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -261.60 -6.94 -9.08 -10.56 -6.04 -5.95 -6.04
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -396.29 -11.22 -15.52 -17.82 -9.30 -8.68 -8.71
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -283.48 -8.26 -11.57 -13.26 -6.71 -6.07 -6.14
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Ultragenyx Pharmaceutical

This table displays calculated financial ratios and metrics derived from Ultragenyx Pharmaceutical's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 96,629,788.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 96,629,788.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.91
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 8.10% 23.27% 8.30% 35.75% 42.27% 29.42% 27.99% 13.24% 14.65% 25.89% -2.16%
EBITDA Growth		 35.93% 18.58% -6.80% 24.04% 12.75% -3.35% 16.69% 12.56% -33.07% 12.14% -19.12%
EBIT Growth		 35.54% 17.49% -8.55% 21.18% 11.58% -4.90% 14.88% 10.53% -33.37% 10.03% -18.18%
NOPAT Growth		 35.53% 16.19% -7.30% 21.35% 9.04% -0.19% 13.55% 7.28% -29.47% 7.38% -18.18%
Net Income Growth		 34.87% 18.86% -4.09% 17.66% 16.37% -8.28% 11.49% 12.65% -35.12% 3.49% -22.52%
EPS Growth		 36.29% 33.64% 12.88% 32.44% 37.22% 6.94% 22.66% 23.03% -29.29% 4.48% -17.20%
Operating Cash Flow Growth		 -23.63% 7.13% -21.59% 33.74% 43.16% 5.25% 12.72% -40.68% -36.46% -25.86% -18.67%
Free Cash Flow Firm Growth		 -150.48% -138.69% -149.90% -136.94% 19.32% 18.30% 37.47% -2.00% -35.01% 337.47% 299.54%
Invested Capital Growth		 8.26% 7.82% 14.20% 10.65% 5.16% 3.78% 3.88% 13.87% 8.43% -67.70% -85.30%
Revenue Q/Q Growth		 -9.47% 29.92% -14.57% 35.09% -5.12% 18.20% -15.52% 19.53% -3.94% 29.60% -34.39%
EBITDA Q/Q Growth		 4.41% 18.08% -39.86% 30.64% -9.79% 2.97% -12.74% 27.19% -67.08% 35.41% -52.91%
EBIT Q/Q Growth		 2.77% 17.69% -39.12% 29.21% -9.07% 2.35% -12.88% 25.58% -62.59% 33.57% -47.96%
NOPAT Q/Q Growth		 1.93% 15.88% -35.48% 29.63% -13.43% 7.36% -16.90% 24.52% -58.40% 33.71% -49.18%
Net Income Q/Q Growth		 0.11% 22.84% -38.55% 22.90% -1.46% 0.10% -13.27% 23.91% -56.95% 28.74% -43.91%
EPS Q/Q Growth		 0.89% 35.43% -40.97% 25.12% 7.89% 4.29% -17.16% 25.48% -54.70% 29.28% -43.75%
Operating Cash Flow Q/Q Growth		 -1.47% 28.82% -127.32% 59.65% 12.95% -18.67% -109.39% 34.96% 15.56% -9.19% -97.34%
Free Cash Flow Firm Q/Q Growth		 -140.27% 12.51% -45.83% 28.11% 12.04% 11.40% -11.61% -17.26% -16.44% 255.46% -5.96%
Invested Capital Q/Q Growth		 -0.35% -1.05% 14.61% -3.19% -6.51% -2.52% 14.70% 7.53% -13.24% -87.87% 5.80%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 88.79% 90.54% 83.89% 85.53% 84.93% 89.75% 79.42% 86.18% 82.50% 85.84% 77.94%
EBITDA Margin		 -144.09% -90.85% -148.73% -76.36% -88.37% -72.55% -96.81% -58.97% -102.56% -51.11% -119.12%
Operating Margin		 -147.98% -95.81% -151.93% -79.14% -94.62% -74.16% -102.62% -64.80% -106.85% -54.65% -124.26%
EBIT Margin		 -148.69% -94.20% -153.40% -80.39% -92.41% -76.35% -102.02% -63.51% -107.50% -55.10% -124.26%
Profit (Net Income) Margin		 -162.82% -96.70% -156.83% -89.51% -95.71% -80.90% -108.46% -69.04% -112.81% -62.02% -136.03%
Tax Burden Percent		 100.41% 97.08% 100.27% 100.66% 100.23% 99.99% 100.87% 100.83% 100.49% 100.68% 100.54%
Interest Burden Percent		 109.06% 105.74% 101.96% 110.62% 103.34% 105.97% 105.40% 107.81% 104.42% 111.79% 108.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -253.84% -193.23% -340.05% -208.43% -289.98% -211.71% -377.06% -180.44% -313.43% -608.47% 1,566.48%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -42.70% -26.94% -50.47% -26.41% -34.80% -28.57% -46.02% -26.50% -49.69% -24.44% -63.85%
Return on Assets (ROA)		 -46.76% -27.66% -51.60% -29.41% -36.04% -30.27% -48.93% -28.81% -52.14% -27.51% -69.89%
Return on Common Equity (ROCE)		 -253.84% -193.23% -340.05% -208.43% -284.71% -208.95% -368.00% -178.30% -301.57% -563.39% 1,848.53%
Return on Equity Simple (ROE_SIMPLE)		 -2,003.16% 0.00% -437.28% -135.31% -161.17% 0.00% -381.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -102 -85 -116 -81 -92 -86 -100 -76 -120 -79 -118
NOPAT Margin		 -103.59% -67.06% -106.35% -55.40% -66.23% -51.91% -71.83% -45.36% -74.80% -38.26% -86.99%
Net Nonoperating Expense Percent (NNEP)		 -7.55% -4.51% -8.53% -6.69% -6.08% -6.28% -9.02% -5.58% -9.56% -6.65% -12.16%
Return On Investment Capital (ROIC_SIMPLE)		 - -31.02% - - - -33.53% -69.37% -49.92% -1,306.07% 99.12% 50.13%
Cost of Revenue to Revenue		 11.21% 9.46% 16.11% 14.47% 15.07% 10.25% 20.58% 13.82% 17.50% 14.16% 22.06%
SG&A Expenses to Revenue		 76.41% 60.31% 71.82% 54.82% 57.60% 50.03% 63.03% 52.04% 54.16% 42.42% 64.71%
R&D to Revenue		 160.37% 126.03% 164.00% 109.85% 121.95% 113.88% 119.01% 98.94% 135.19% 98.07% 137.50%
Operating Expenses to Revenue		 236.77% 186.35% 235.82% 164.67% 179.55% 163.92% 182.04% 150.98% 189.35% 140.50% 202.21%
Earnings before Interest and Taxes (EBIT)		 -146 -120 -167 -118 -129 -126 -142 -106 -172 -114 -169
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -141 -116 -162 -112 -123 -120 -135 -98 -164 -106 -162
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 80.36 14.26 27.33 7.90 14.76 15.22 23.22 22.72 316.50 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 60.66 0.00 15.41 37.24 119.25 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 6.21 9.04 8.66 7.10 9.79 6.93 5.67 5.63 4.60 3.30 3.02
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 4.93 7.25 7.38 5.28 8.23 5.62 4.73 4.76 3.90 2.21 2.23
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -3.07 -2.67 -3.57 -2.67 -3.51 -2.83 -3.88 -2.39 -3.44 -7.84 14.11
Leverage Ratio		 5.71 4.84 7.46 5.22 7.20 5.57 8.98 4.95 7.38 16.06 -33.54
Compound Leverage Factor		 6.22 5.11 7.60 5.77 7.44 5.90 9.47 5.34 7.70 17.95 -36.52
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 1.98% 2.67% 4.63% 4.42% 43.32% -9.59% -3.06%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 98.02% 97.33% 95.37% 95.58% 56.68% 109.59% 103.06%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.15 -0.85 -1.60 -0.89 -0.42 -1.33 -2.19 -2.14 -3.34 -2.67 -3.91
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 1.82% 1.30% 2.40% 1.19% 3.78% 7.41% -18.01%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.36 2.61 2.43 3.54 2.81 2.37 2.40 2.45 1.89 2.48 2.02
Quick Ratio		 2.05 2.32 2.09 3.19 2.51 2.13 2.03 2.09 1.58 2.18 1.64
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -146 -128 -187 -134 -118 -105 -117 -137 -159 248 233
Operating Cash Flow to CapEx		 -3,190.09% -5,244.00% -5,939.80% -3,830.91% -4,143.17% -12,156.42% -12,573.64% -4,401.34% -7,153.60% -10,642.75% -19,700.00%
Free Cash Flow to Firm to Interest Expense		 -8.28 -7.39 -11.78 -8.41 -7.51 -6.74 -8.14 -9.75 -11.26 12.72 11.09
Operating Cash Flow to Interest Expense		 -6.67 -4.84 -12.04 -4.82 -4.26 -5.12 -11.61 -7.71 -6.46 -5.13 -9.38
Operating Cash Flow Less CapEx to Interest Expense		 -6.88 -4.93 -12.24 -4.95 -4.37 -5.16 -11.70 -7.89 -6.55 -5.18 -9.43
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.29 0.29 0.33 0.33 0.38 0.37 0.45 0.42 0.46 0.44 0.51
Accounts Receivable Turnover		 7.43 7.63 6.18 5.45 6.06 5.74 5.93 5.30 6.13 4.81 6.10
Inventory Turnover		 1.43 1.49 1.61 1.81 1.91 1.94 2.14 2.07 2.02 2.25 2.18
Fixed Asset Turnover		 1.54 1.58 1.57 1.70 1.84 2.01 2.16 2.28 2.41 2.64 2.68
Accounts Payable Turnover		 1.35 1.06 1.01 1.21 2.07 1.90 1.99 1.90 2.52 3.11 2.46
Days Sales Outstanding (DSO)		 49.13 47.84 59.07 66.93 60.25 63.59 61.51 68.93 59.57 75.93 59.88
Days Inventory Outstanding (DIO)		 254.47 245.18 226.02 201.80 190.75 187.85 170.20 176.50 180.58 162.41 167.62
Days Payable Outstanding (DPO)		 269.83 344.69 361.32 300.74 176.06 192.35 183.67 191.61 144.72 117.20 148.41
Cash Conversion Cycle (CCC)		 33.77 -51.68 -76.24 -32.01 74.94 59.08 48.04 53.82 95.43 121.14 79.10
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -496 -502 -428 -442 -471 -483 -412 -381 -431 -810 -763
Invested Capital Turnover		 -0.79 -0.83 -0.95 -1.03 -1.08 -1.14 -1.41 -1.48 -1.40 -1.04 -1.14
Increase / (Decrease) in Invested Capital		 45 43 71 53 26 19 17 61 40 -327 -351
Enterprise Value (EV)		 2,020 3,150 3,265 2,542 4,302 3,147 2,793 2,906 2,459 1,489 1,497
Market Capitalization		 2,549 3,927 3,834 3,417 5,120 3,885 3,349 3,438 2,899 2,219 2,024
Book Value per Share		 $0.44 $3.35 $1.66 $5.20 $3.76 $2.76 $1.56 $1.60 $0.10 ($0.83) ($2.44)
Tangible Book Value per Share		 ($2.38) $0.79 ($0.82) $2.67 $1.49 $0.35 ($0.83) ($0.72) ($2.16) ($3.11) ($4.70)
Total Capital		 32 275 140 432 354 262 151 158 16 -73 -229
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -528 -777 -569 -874 -825 -745 -563 -539 -447 -737 -534
Capital Expenditures (CapEx)		 3.70 1.60 3.21 2.01 1.62 0.65 1.32 2.46 1.28 0.94 1.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -97 -125 -62 -72 -107 -137 -87 -61 -122 -113 -81
Debt-free Net Working Capital (DFNWC)		 345 452 350 692 515 473 407 427 303 567 332
Net Working Capital (NWC)		 345 452 350 692 515 473 407 427 303 567 332
Net Nonoperating Expense (NNE)		 58 38 55 50 41 48 51 39 61 49 67
Net Nonoperating Obligations (NNO)		 -528 -777 -569 -874 -825 -745 -563 -539 -447 -737 -534
Total Depreciation and Amortization (D&A)		 4.51 4.27 5.09 5.92 5.64 6.27 7.26 7.57 7.90 8.27 7.00
Debt-free, Cash-free Net Working Capital to Revenue		 -23.62% -28.89% -13.94% -14.97% -20.47% -24.46% -14.72% -10.00% -19.36% -16.79% -12.09%
Debt-free Net Working Capital to Revenue		 84.16% 104.03% 79.17% 143.73% 98.44% 84.42% 68.99% 69.91% 48.08% 84.25% 49.55%
Net Working Capital to Revenue		 84.16% 104.03% 79.17% 143.73% 98.44% 84.42% 68.99% 69.91% 48.08% 84.25% 49.55%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.23) ($1.44) ($2.03) ($1.52) ($1.40) ($1.34) ($1.57) ($1.17) ($1.81) ($1.28) ($1.84)
Adjusted Weighted Average Basic Shares Outstanding		 71.66M 73.54M 84.29M 86.58M 95.49M 90.54M 96.29M 98.46M 99.77M 98.60M 100.60M
Adjusted Diluted Earnings per Share		 ($2.23) ($1.44) ($2.03) ($1.52) ($1.40) ($1.34) ($1.57) ($1.17) ($1.81) ($1.28) ($1.84)
Adjusted Weighted Average Diluted Shares Outstanding		 71.66M 73.54M 84.29M 86.58M 95.49M 90.54M 96.29M 98.46M 99.77M 98.60M 100.60M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 82.11M 82.34M 83.13M 92.17M 92.34M 92.50M 94.54M 96.37M 96.48M 96.63M 98.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -102 -85 -116 -81 -92 -86 -100 -76 -120 -79 -118
Normalized NOPAT Margin		 -103.59% -67.06% -106.35% -55.40% -66.23% -51.91% -71.83% -45.36% -74.80% -38.26% -86.99%
Pre Tax Income Margin		 -162.16% -99.61% -156.41% -88.92% -95.50% -80.91% -107.52% -68.47% -112.26% -61.60% -135.29%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -8.25 -6.93 -10.54 -7.41 -8.20 -8.11 -9.91 -7.53 -12.15 -5.87 -8.05
NOPAT to Interest Expense		 -5.75 -4.93 -7.30 -5.10 -5.88 -5.51 -6.98 -5.38 -8.46 -4.07 -5.63
EBIT Less CapEx to Interest Expense		 -8.46 -7.02 -10.74 -7.53 -8.31 -8.15 -10.00 -7.71 -12.24 -5.91 -8.10
NOPAT Less CapEx to Interest Expense		 -5.96 -5.02 -7.51 -5.23 -5.98 -5.56 -7.07 -5.55 -8.55 -4.12 -5.68
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Below is a concise, investor-focused synopsis of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) using the latest quarterly data provided. The highlights focus on multi-year trends across revenue, profitability, and liquidity, with a view toward how these may impact a retail investor’s view of the stock.

  • Gross margin in Q4 2025 was strong at about 85.8% (Total Gross Profit of $177,934,000 on Revenue of $207,279,000).
  • Q4 2025 revenue rose to $207,279,000, up from $164,877,000 in Q4 2024, indicating top-line momentum compared with the prior year.
  • Liquidity received a sizable boost in Q4 2025 from financing activities: Net Cash From Financing Activities of $394,192,000, including issuance of Common Equity of $2,192,000.
  • Net change in cash for Q4 2025 was +$221,460,000, reflecting the financing inflow and improving near-term liquidity.
  • Cash and equivalents trended higher in 2025, rising from about $127.1M (Q1 2025) to roughly $202.5M (Q3 2025) before the Q4 financing, indicating improving liquidity dynamics independent of operating cash flow.
  • R&D expense remains a major cost driver (Q4 2025 RD expense about $203.3M), consistent with Ultragenyx’ pipeline-focused model and typical for biotech, but it weighs on profits.
  • Earnings per share remained negative in Q4 2025 (Basic EPS -$1.28; Diluted EPS -$1.28) as a function of the continued net losses and share count.
  • Net income attributable to common shareholders in Q4 2025 was -$128,556,000, continuing a trend of quarterly losses.
  • Cash flow from continuing operating activities was negative in Q4 2025, at -$99,829,000, signaling ongoing cash burn despite the year-end financing.
  • Total operating income in Q4 2025 remained negative at -$113,283,000, even as revenue grew, highlighting profitability headwinds from high operating costs.
05/14/26 06:23 PM ETAI Generated. May Contain Errors.

Ultragenyx Pharmaceutical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Ultragenyx Pharmaceutical's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Ultragenyx Pharmaceutical's net income appears to be on an upward trend, with a most recent value of -$575 million in 2025, rising from -$145.62 million in 2015. The previous period was -$569 million in 2024. Check out Ultragenyx Pharmaceutical's forecast to explore projected trends and price targets.

Ultragenyx Pharmaceutical's total operating income in 2025 was -$535 million, based on the following breakdown:
  • Total Gross Profit: $564 million
  • Total Operating Expenses: $1.10 billion

Over the last 10 years, Ultragenyx Pharmaceutical's total revenue changed from $0.00 in 2015 to $673 million in 2025, a change of 67,300,000,000.0%.

Ultragenyx Pharmaceutical's total liabilities were at $1.61 billion at the end of 2025, a 29.3% increase from 2024, and a 5,535.7% increase since 2015.

In the past 10 years, Ultragenyx Pharmaceutical's cash and equivalents has ranged from $93.57 million in 2015 to $713.53 million in 2020, and is currently $421 million as of their latest financial filing in 2025.

Over the last 10 years, Ultragenyx Pharmaceutical's book value per share changed from 13.68 in 2015 to -0.83 in 2025, a change of -106.1%.


Related Companies

Financial statements for NASDAQ:RARE last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Distracted Americans set to miss out on quadrillions
Technology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...
Brownstone Research | Sponsoredtc pixel